Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference

CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual 2020 Healthcare Conference on Tuesday, June 2, 2020, at 1:00 p.m. ET.

A live audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM^® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:

Lori Melançon
Vice President, Corporate Affairs
+1 (617) 949-5296
[email protected]

Media Contact: 
Dan Budwick
1AB
+1 (973) 271-6085
[email protected]

You May Also Be Interested In

• The 80/20 Institute Introduces an Approach to Expand Margin Without Cutting — by Concentrating on the 20% That Drives Profit
• QAIAx Clinical Trial: AGI Alternative Sentencing & Reality Pro-Social Dating (Veterans First for America)
• Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Provides New Details on Upgrading Its Robotics Strategy to the “Four-Core Full-Stack AI” and Q3 Robotics Practical Deplo